A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2

ClinicalTrials.gov ID: NCT05514717

Public ClinicalTrials.gov record NCT05514717. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Apr 29, 2026, 9:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1, First-in-Human, Dose Escalation and Expansion, Multicenter Study of XMT-2056 in Participants With Advanced/Recurrent Solid Tumors That Express HER2

Study identification

NCT ID: NCT05514717
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1
Lead sponsor: Mersana Therapeutics; Industry
Enrollment: 162 participants

Conditions and interventions

Conditions

Interventions

XMT-2056 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 23, 2023
Primary completion: Mar 31, 2027
Completion: Mar 31, 2027
Last update posted: Jul 10, 2025

2023 – 2027

United States locations

U.S. sites: 14
U.S. states: 10
U.S. cities: 11

Facility	City	State	ZIP	Site status
University of South California	Los Angeles	California	90033	Recruiting
University of California Los Angeles	Los Angeles	California	90095	Recruiting
Stanford University Medical Center	Stanford	California	94305	Recruiting
AdventHealth Celebration	Celebration	Florida	34747	Recruiting
Emory Healthcare, Emory Clinic	Atlanta	Georgia	30322	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Karmanos Cancer Institute	Detroit	Michigan	48201	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
New York University Medical Oncology Associates	New York	New York	10016	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
The Ohio State University Comprehensive Cancer Center	Columbus	Ohio	43212	Recruiting
Tennessee Oncology, PLLC	Nashville	Tennessee	37203	Recruiting
The University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT05514717, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jul 10, 2025 · Synced Apr 29, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05514717 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →